Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Autor: Kruti Patel, Leonard Jeff Harris, Michael Gary Martin
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Immunoconjugates
medicine.medical_treatment
Aggressive lymphoma
Review
lcsh:Chemistry
0302 clinical medicine
immune system diseases
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Refractory Diffuse Large B-Cell Lymphoma
lcsh:QH301-705.5
Lenalidomide
Spectroscopy
oncology_oncogenics
Antibodies
Monoclonal
General Medicine
Adoptive Transfer
Computer Science Applications
Polatuzumab vedotin
Hydrazines
Relapsed or Refractory Diffuse Large B Cell Lymphoma
030220 oncology & carcinogenesis
Lymphoma
Large B-Cell
Diffuse
immunotherapy
medicine.drug
medicine.medical_specialty
DLBLC
Antibodies
Monoclonal
Humanized
Catalysis
Inorganic Chemistry
03 medical and health sciences
Internal medicine
medicine
Humans
Physical and Theoretical Chemistry
Molecular Biology
business.industry
Organic Chemistry
Immunotherapy
Triazoles
chemotherapy-free regimen
medicine.disease
Chimeric antigen receptor
Lymphoma
Regimen
030104 developmental biology
lcsh:Biology (General)
lcsh:QD1-999
business
Zdroj: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 21, Iss 8553, p 8553 (2020)
ISSN: 1422-0067
Popis: The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged remissions achieved in some patients. Anti-CD19 CAR (chimeric antigen receptor) T cells are potentially curative in the 3rd line and beyond setting and are under investigation in earlier lines of therapy. Antibody-drug conjugates (ADC’s) such as polatuzumab vedotin targeting the pan-B-cell marker CD79b has proven effectiveness in multiply-relapsed DLBCL patients. Tafasitamab (MOR208) is an anti-CD19 monoclonal antibody producing prolonged remissions when combined with Lenalidomide (LEN) in patients who were not candidates for salvage chemotherapy or autologous stem cell transplant. Selinexor, an oral, small-molecule selective inhibitor of XPO1-mediated nuclear export (SINE), demonstrated prolonged activity against heavily-pretreated DLBCL without cumulative toxicity and is being investigated as part of an oral, chemotherapy-free regimen for relapsed aggressive lymphoma. This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje